{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"INTerpath-007","nct_id":"NCT06295809","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interpath-007-nct06295809. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"INTerpath-007","arms":[{"description":"Participants will receive intismeran autogene 1 mg intramuscular (IM) injection every 3 weeks (q3w) for up to 6 weeks and pembrolizumab 400 mg intravenous (IV) infusion every 6 weeks (q6w) up to 12 weeks as neoadjuvant therapy prior to surgery; followed by intismeran autogene 1 mg IM injection q3w up to 21 weeks.","label":"Pembrolizumab plus Intismeran autogene with SOC","type":"EXPERIMENTAL"},{"description":"Participants will receive surgical resection as per local guidelines with/without adjuvant radiation therapy (RT) at investigator's discretion.","label":"Standard of Care (SOC)","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive pembrolizumab 400 mg IV infusion q6w up to 12 weeks as neoadjuvant therapy prior to surgery.","label":"Pembrolizumab with SOC","type":"EXPERIMENTAL"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2026-03-05","type":"ACTUAL"},"conditions":["Carcinoma, Squamous Cell","Skin Neoplasms"],"enrollment":{"count":46,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475","Keytruda®"],"type":"BIOLOGICAL"},{"name":"Intismeran autogene","otherNames":["mRNA-4157","V940"],"type":"BIOLOGICAL"},{"name":"Surgery","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-05-08","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 2/3, Adaptive, Randomized, Open-label, Clinical Study to Evaluate Neoadjuvant and Adjuvant Intismeran Autogene (mRNA-4157) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care, and Pembrolizumab Monotherapy in Participants With Resectable Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (INTerpath-007)","overall_status":"TERMINATED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2026-03-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event Free Survival (EFS)","timeFrame":"Up to ~22 months"}],"references":[],"start_date":{"date":"2024-04-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)","url":"https://clinicaltrials.gov/study/NCT06295809"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interpath-007-nct06295809"}